Study Evaluating the Efficacy of DVS-233 in Fibromyalgia

• Status: Terminated
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Fibromyalgia according to 1990 American College of Rheumatology (ACR) criteria

Exclusion Criteria:

• Other painful conditions that may make results difficult to interpret.

• Treatment with other drugs for fibromyalgia with 14 days of study start or during the study.